公开(公告)号：US12029789B2

公开(公告)日：2024-07-09

申请号：US17568757

申请日：2022-01-05

Applicant: DC EUROPA LIMITED

Inventor： Matthias Osswald ,  Wolfgang Wick ,  Frank Winkler ,  Erik Jung ,  Jonas Blaes

IPC: A61K39/395 ,  A61K31/13 ,  A61K31/155 ,  A61K31/16 ,  A61K31/495 ,  A61K31/497 ,  A61K31/4985 ,  A61K31/515 ,  A61K31/522 ,  A61K31/5377 ,  A61K31/7105 ,  A61K31/713 ,  A61P35/00 ,  C12N15/113

CPC classification number: A61K39/39558 ,  A61K31/13 ,  A61K31/155 ,  A61K31/495 ,  A61K31/4985 ,  A61K31/522 ,  A61K31/7105 ,  A61K31/713 ,  A61P35/00 ,  C12N15/113 ,  C12N15/1138 ,  A61K31/16 ,  A61K31/497 ,  A61K31/515 ,  A61K31/5377 ,  A61K2300/00 ,  C12N2310/14 ,  C12N2330/50

Abstract: The present invention relates to agents for use in the treatment of glioma, in particular astrocytoma WHO II° and III°, as well as IV° (glioblastoma), in a subject.

公开(公告)号：US11987605B2

公开(公告)日：2024-05-21

申请号：US17025717

申请日：2020-09-18

Applicant: Helix Nanotechnologies Inc

Inventor： Taylor Gill ,  Hannu Rajaniemi ,  Nikolai Eroshenko

IPC: C07K14/47 ,  C12N5/10 ,  C12N5/16 ,  C12N15/63

CPC classification number: C07K14/4703 ,  C12N5/10 ,  C12N5/16 ,  C12N15/63 ,  C07K2319/09 ,  C07K2319/70 ,  C12N2330/50

Abstract: The present disclosure provides technologies for MYC inhibition, including, e.g. MYC fusion polypeptides and compositions comprising the same as well as methods of using the same. In particular, the present disclosure, among others, provides fusion polypeptides comprising a mutant MYC polypeptide and a repressor domain. In some embodiments, such fusion polypeptides and compositions comprising the same can be useful for inducing cancer cell apoptosis. Accordingly, in some embodiments, such fusion polypeptides and compositions comprising the same can be useful for cancer treatment.

公开(公告)号：US20230285508A1

公开(公告)日：2023-09-14

申请号：US18198519

申请日：2023-05-17

Applicant: SynPhaGen LLC

Inventor： Todd Bernard Parsley ,  Christian Furlan Freguia

IPC: A61K38/20 ,  C02F3/34 ,  A61K38/45 ,  C12N15/113 ,  C12N15/86 ,  A61K38/48 ,  C12N15/11 ,  A61K48/00 ,  C12N15/70 ,  C12N7/00

CPC classification number: A61K38/2066 ,  C02F3/34 ,  A61K38/45 ,  C12N15/113 ,  C12N15/86 ,  C12Y203/02013 ,  A61K38/482 ,  C12N15/111 ,  A61K48/005 ,  C12N15/70 ,  C12N7/00 ,  C12Y201/02001 ,  C12N2310/14 ,  C12N2795/00031 ,  C12N2320/32 ,  C12N2330/50 ,  C12N2795/00032 ,  C12N2795/00021 ,  C12N2820/55 ,  C12N2795/14143 ,  C12N2795/00043 ,  C12N2310/531

Abstract: Compositions for a phage particle are disclosed. The phage particle is non-replicating and includes at least one heterologous nucleic acid sequence that is capable of being expressed in a target bacteria. The expressed heterologous nucleic acid sequence is non-lethal to the target bacteria.

公开(公告)号：US11718851B2

公开(公告)日：2023-08-08

申请号：US16922948

申请日：2020-07-07

Applicant: RNAISSANCE AG LLC

Inventor： John L. Killmer ,  Patrick D. McLaughlin ,  Juan Pedro Humberto Arhancet

IPC: C12N15/113 ,  C12N15/11 ,  C07K14/005

CPC classification number: C12N15/113 ,  C07K14/005 ,  C12N15/111 ,  C12N2310/14 ,  C12N2330/50 ,  C12N2795/18122

Abstract: The invention provides methods and compositions for improved production of large quantities of unencapsidated double strand RNA (dsRNA) in vivo. The disclosed methods and compositions, comprising co-expression of genes encoding orotate phosporibosyl transferase, bacteriophage coat protein and dsRNA produce a significant improvement over current in vivo methods of producing unencapsidated dsRNA.

公开(公告)号：US20230227816A1

公开(公告)日：2023-07-20

申请号：US18009549

申请日：2021-06-15

Applicant: CHAN ZUCKERBERG BIOHUB, INC. ,  THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

Inventor： Richard Felix Horns ,  Stephen R. Quake

IPC: C12N15/10 ,  C12N15/63 ,  C12Q1/686 ,  C07K16/00

CPC classification number: C12N15/1096 ,  C12N15/63 ,  C12Q1/686 ,  C07K16/005 ,  C07K2317/10 ,  C12N2330/50

Abstract: The present disclosure provides materials and methods for cloning antibodies from single cells in pooled sequence libraries by selective PCR. The compositions and methods relate to isolating, cloning, and/or expressing one or more antibody sequences from a single cell from a pool of cells.

公开(公告)号：US20230183759A1

公开(公告)日：2023-06-15

申请号：US17926487

申请日：2021-05-20

Applicant: Wisconsin Alumni Research Foundation

Inventor： Brian F. Pfleger ,  Qiang Yan ,  Trevor R. Simmons ,  Nestor Hernandez-Lozada

IPC: C12P7/26 ,  C12N15/52 ,  C12N15/74 ,  C12N9/16 ,  C12N9/00 ,  C12N9/04

CPC classification number: C12P7/26 ,  C12N15/52 ,  C12N15/74 ,  C12N9/16 ,  C12N9/93 ,  C12N9/0006 ,  C12Y101/01035 ,  C12Y402/01017 ,  C12Y602/01001 ,  C12Y301/0202 ,  C12Y301/02021 ,  C12N2330/50

Abstract: Recombinant cells and methods for producing methyl ketones, such as medium-chain methyl ketones. The recombinant cells include recombinant acyl-ACP thioesterase genes, recombinant β-ketoacyl-CoA thioesterase genes, and recombinant acyl-CoA synthetase genes, in addition to other modifications. The methods include culturing the recombinant cells to produce the methyl ketones and isolating the produced methyl ketones.

公开(公告)号：US20190185820A1

公开(公告)日：2019-06-20

申请号：US16319749

申请日：2017-08-23

Applicant: The Regents of the University of California

Inventor： Danica Chen ,  Hanzhi Luo

IPC: C12N5/16 ,  C12N15/85 ,  C12N15/113 ,  A61K35/28 ,  C12N5/074 ,  A61P25/28 ,  A61P21/00 ,  A61K31/7105 ,  A61K31/4453

CPC classification number: C12N5/16 ,  A61K31/4453 ,  A61K31/7088 ,  A61K31/7105 ,  A61K31/713 ,  A61K35/28 ,  A61K45/06 ,  A61P21/00 ,  A61P25/28 ,  C12N5/0607 ,  C12N5/0647 ,  C12N15/1137 ,  C12N15/85 ,  C12N2310/14 ,  C12N2310/531 ,  C12N2330/50 ,  C12N2501/998 ,  C12N2501/999 ,  C12N2510/00

Abstract: The present disclosure provides methods of improving the function of stem cells, and/or reducing or inhibiting or inhibiting stem cell aging.

公开(公告)号：US20180265879A1

公开(公告)日：2018-09-20

申请号：US15760263

申请日：2016-09-13

Applicant: Advaxis, Inc. ,  The Trustees of the University of Pennsylvania

Inventor： Anu Wallecha ,  Yvonne Paterson

IPC: C12N15/74 ,  C12P21/00 ,  C07K14/195 ,  C07K14/025 ,  C07K19/00 ,  A61K39/12

CPC classification number: C12N15/74 ,  A61K35/74 ,  A61K39/0011 ,  A61K39/12 ,  A61K2039/585 ,  A61K2039/6068 ,  A61K2039/6075 ,  A61K2039/892 ,  A61P35/00 ,  C07K14/005 ,  C07K14/025 ,  C07K14/195 ,  C07K19/00 ,  C07K2319/06 ,  C07K2319/55 ,  C12N1/20 ,  C12N5/00 ,  C12N2330/50 ,  C12N2511/00 ,  C12N2710/20022 ,  C12N2710/20033 ,  C12N2710/20034 ,  C12N2710/20043 ,  C12N2710/20051 ,  C12N2740/16234 ,  C12N2800/101 ,  C12P21/00

Abstract: The present invention discloses a process for manufacturing a formulation comprising a drug substance, said drug substance comprising a recombinant Listeria comprising a human papilloma virus (HPV) antigen fused to a Listeriolysin O (LLO) protein fragment. The invention further discloses methods of using treating, protecting against, and inducing an immune response against cervical cancer comprising administration of the recombinant Listeria strain. The present invention also provides methods for inducing an anti-E7 CTL response in a human subject and treating HPV-mediated diseases, disorders, and symptoms, comprising administration of the recombinant Listeria strain.

公开(公告)号：US20180237847A1

公开(公告)日：2018-08-23

申请号：US15752884

申请日：2016-08-19

Applicant: GENOMATICA, INC.

Inventor： Stephanie CULLER ,  Ihsiung Brandon CHEN ,  Priti PHARKYA ,  Steve VAN DIEN ,  Nelson BARTON

IPC: C12Q1/6869 ,  C12N15/09 ,  C12N5/16 ,  A61K36/02 ,  A61K35/66 ,  A61K36/06 ,  C40B40/04

CPC classification number: C12Q1/6869 ,  A61K35/66 ,  A61K36/02 ,  A61K36/06 ,  A61K2236/15 ,  A61K2236/30 ,  C12N5/16 ,  C12N15/09 ,  C12N2330/50 ,  C12P19/34 ,  C12P21/02 ,  C40B40/04 ,  Y02A50/409 ,  Y02A50/469 ,  A61K35/12

Abstract: In alternative embodiments, provided herein are transcription/translation (TX-TL) systems and methods of using them for use as rapid prototyping platforms for the synthesis, modification and identification of natural products (NPs), and natural product analogs (NPAs) and secondary metabolites, from biosynthetic gene cluster pipelines. In alternative embodiments, exemplary TX-TL systems as provided herein are used for the combinatorial biosynthesis of natural products (NPs), natural product analogs (NPAs) and secondary metabolites. In alternative embodiments, exemplary TX-TL systems as provided herein are used for the rapid prototyping of complex biosynthetic pathways as a way to rapidly assess combinatorial and biosynthetic designs before moving to cellular hosts. In alternative embodiments, these exemplary TX-TL systems are multiplexed for high-throughput (HT) automation and for prototyping engineered platforms for the synthesis or modification of natural products (NPs), and natural product analogs (NPAs) and secondary metabolites analogs.

公开(公告)号：US20180135046A1

公开(公告)日：2018-05-17

申请号：US15351768

申请日：2016-11-15

Applicant: City University of Hong Kong

Inventor： Linfeng Huang ,  Yutian Ren ,  Hung-chi Cheung ,  Guneet Kaur

IPC: C12N15/113

CPC classification number: C12N15/113 ,  C12N2310/14 ,  C12N2320/12 ,  C12N2330/50

Abstract: A method of preparing a library of small interfering RNA (siRNA) expression systems for producing siRNA for silencing of target genes by inducing degradation of target gene RNA expression products includes: (i) isolating RNA of one or more target genes from a cell population; (ii) generating RNA fragments from the isolated RNA; (iii) converting the RNA fragments into dsDNA fragments; and (iv) cloning the dsDNA fragments into vectors for forming cloned vectors, each vector including one or more promoters and at least one restriction enzyme site capable of accepting the insertion of at least one dsDNA fragment such that siRNA can be produced. Methods for producing siRNA from the siRNA expression system and methods of identifying a functional target gene for treatment by using the siRNA produced from the siRNA expression system and for identifying RNAi therapeutics are also provided.